Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in Hepatitis C Patients
- *Corresponding Author:
- Manal Mohamed Saber
Clinical Pathology Department
Faculty of Medicine
Minia University, Egypt
E-mail: [email protected]
Received date: June 23, 2016; Accepted date: August 05, 2016; Published date: August 10, 2016
Citation: Saber MM, Clauss M (2016) Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in Hepatitis C Patients. Immunome Res 12:117. doi:10.4172/1745-7580.10000117
Copyright: © 2016 Saber MM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Endothelial monocyte-activating polypeptide-II (EMAP-II) is a cytokine with pro-inflammatory and immune-suppressive properties. The goal of this study was to assess serum EMAP-II in treated and untreated Hepatitis C virus (HCV) patients. Furthermore, we determined the relationship between serum EMAP-II levels with the clinic pathological and laboratory parameters in patients with HCV. Methods: 25 control patients (Group I), 25 treated HCV patients (Group II) and 25 newly diagnosed, untreated patients with HCV (Group III) were included in this study. Serum EMAP-II levels were detected by Enzyme linked immunosorbent assay (ELISA), and HCV RNA was assessed by real time-PCR (RT-PCR). The results were evaluated against clinical and laboratory data. Results: Serum EMAP-II levels were significantly elevated in newly diagnosed, untreated HCV patients compared to treated HCV and control patients (p<0.001). We found that serum EMAP-II levels correlated positively with HCV RNA in untreated HCV patients (p<0.001). While serum albumin and platelet count correlated negatively with serum EMAP-II levels (p<0.001), a positive correlation was observed between EMAP-II and serum bilirubin (p<0.001). Conclusions: Increased serum EMAP-II levels are present in newly diagnosed HCV patients compared to treated HCV and control patients, suggesting EMAP-II as a novel biomarker for HCV diagnosis.